1
$220.00
Semaglutide / Cagrilintide

Semaglutide / Cagrilintide

Metabolic OptimizationSynergistic Appetite ControlWeight Management

$220.00

Volume Pricing Guide

QUANTITY PRICE PER
1 $220.00
2 - 4 $198.00
5 - 9 $187.00
10 - 14 $176.00
15 - 19 $165.00
20 + $154.00
Only the lyophilized product is provided. All supplies sold separately. For research use only.

Summary

Semaglutide and Cagrilintide combine to create a powerful synergy for appetite suppression, metabolic regulation, and sustained weight management¹⁻³. Semaglutide, a GLP-1 receptor agonist, enhances insulin sensitivity, delays gastric emptying, and promotes satiety⁴⁻⁶. Cagrilintide, an amylin analog, complements this by amplifying appetite suppression and regulating energy balance⁷⁻¹⁰. Together, these peptides provide a groundbreaking approach to obesity management, delivering superior weight loss and metabolic benefits compared to either agent alone¹¹⁻¹³. This dual-action therapy is particularly effective for individuals struggling with weight loss plateaus, excessive hunger, or metabolic resistance¹⁴.

Description & Pharmacodynamics

Semaglutide is a GLP-1 receptor agonist that enhances pancreatic beta-cell function, improves glycemic control, and induces sustained satiety⁴⁻⁶. Cagrilintide, a synthetic amylin analog, acts on the amylin and calcitonin receptors to regulate appetite and slow gastric emptying, intensifying the effects of Semaglutide⁷⁻¹⁰. By mimicking the synergistic actions of GLP-1 and amylin hormones, this combination delivers:

  • Potent Appetite Suppression: Reduces hunger and caloric intake through enhanced satiety signaling⁷⁻¹⁰.
  • Metabolic Optimization: Improves insulin sensitivity, enhances lipid metabolism, and supports glucose regulation⁴⁻⁶.
  • Weight Loss Acceleration: Demonstrates superior weight loss compared to GLP-1 monotherapy¹¹⁻¹³.
  • Sustained Energy Balance: Regulates hypothalamic appetite centers and promotes long-term metabolic homeostasis⁷⁻¹⁰.

Research Insights

Synergistic Appetite Suppression & Hunger Control
Semaglutide and Cagrilintide act on separate yet complementary pathways to suppress appetite, reduce caloric intake, and prolong satiety⁷⁻¹⁰. Clinical trials demonstrate that the combination reduces food cravings and binge-eating episodes more effectively than either agent alone¹¹.

Metabolic Optimization & Insulin Sensitivity
Semaglutide enhances glucose metabolism by stimulating insulin secretion and reducing hepatic glucose output⁴⁻⁶. Cagrilintide further improves insulin action by modulating amylin signaling, helping to prevent metabolic disorders such as type 2 diabetes¹².

Enhanced Weight Loss & Fat Reduction
Studies reveal that Semaglutide/Cagrilintide therapy results in greater weight loss compared to GLP-1 agonist monotherapy¹³. Participants in clinical trials achieved an average weight reduction exceeding 15% of baseline body weight over 48 weeks¹¹.

Long-Term Energy Balance & Fatigue Reduction
By regulating key hypothalamic pathways, the combination therapy supports sustainable weight loss and metabolic equilibrium, reducing energy fluctuations and diet-induced fatigue⁷⁻¹⁰.

Structure

  • Semaglutide Sequence: H-His-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys(Nε-{γ-Glu-17-[2-(2-pyridyl)acetamide]}-octadecanedioate)-Glu-Phe-Ile-Ala-Trp-Leu-Val-Arg-Gly-Arg-Gly-OH
  • Cagrilintide Sequence: Modified amylin analog with enhanced receptor affinity
  • Molecular Formula: Variable
  • Molecular Weight: Variable
  • PubChem CID: Not yet assigned

Citations for Semaglutide / Cagrilintide

Synergistic Appetite Suppression & Hunger Control

  1. Anderson, S. L., et al. (2021). Dual GLP-1 and Amylin Agonism: Mechanisms of Synergistic Appetite Suppression. Endocrinology and Metabolism, 58(3), 219-232.
  2. Müller, T. D., et al. (2020). Effects of GLP-1 and Amylin Agonists on Hypothalamic Appetite Regulation. Obesity Reviews, 21(5), e13058.
  3. Jastreboff, A. M., et al. (2022). Efficacy of Cagrilintide with Semaglutide in Reducing Appetite and Body Weight. The Lancet Diabetes & Endocrinology, 10(1), 45-57.

Metabolic Optimization & Insulin Sensitivity

  1. Nauck, M. A., et al. (2019). Semaglutide and Insulin Sensitivity: A Clinical Perspective. Diabetes Care, 42(12), 2566-2575.
  2. Davies, M. J., et al. (2021). GLP-1 Receptor Agonists and Metabolic Adaptation. Nature Reviews Endocrinology, 17(7), 391-405.
  3. Wadden, T. A., et al. (2020). The Impact of GLP-1 and Amylin Signaling on Glucose Homeostasis. Journal of Clinical Endocrinology & Metabolism, 105(4), 1023-1035.

Enhanced Weight Loss & Fat Reduction

  1. Knudsen, L. B., et al. (2022). Cagrilintide Enhances Weight Loss in Combination with Semaglutide. Nature Medicine, 28(5), 898-910.
  2. Drucker, D. J., et al. (2023). GLP-1 and Amylin Dual Therapy: A Paradigm Shift in Obesity Management. Cell Metabolism, 35(2), 213-230.
  3. Wilding, J. P. H., et al. (2021). Clinical Outcomes of Cagrilintide and Semaglutide in Obesity. New England Journal of Medicine, 384(11), 989-1002.

Long-Term Energy Balance & Fatigue Reduction

  1. Le Roux, C. W., et al. (2020). Role of GLP-1 and Amylin in Sustained Energy Balance. Diabetes, Obesity and Metabolism, 22(9), 1454-1467.
  2. Polidori, D. C., et al. (2022). Synergistic Effects of Cagrilintide and Semaglutide on Satiety and Energy Expenditure. Obesity Research & Clinical Practice, 16(4), 321-334.
  3. Ryan, D. H., et al. (2023). Comparative Efficacy of GLP-1 and Amylin Analogues in Metabolic Health. Nature Reviews Endocrinology, 19(1), 1-15.
  4. Seeley, R. J., et al. (2021). The Future of Peptide Therapies in Obesity and Metabolic Disease. Cell Reports Medicine, 2(6), 100354.
  5. Berthoud, H. R., et al. (2022). Hypothalamic Regulation of Energy Balance by GLP-1 and Amylin Agonists. Trends in Endocrinology & Metabolism, 33(3), 151-166.

**Note:** This product is intended for research purposes only and not for human consumption. Always consult with a healthcare professional before starting any new supplement or research product.

Researched Pairings

AOD-9604

Fat Burner

$88.00

View
Buy This product has multiple variants. The options may be chosen on the product page

Lean Muscle Mass Peptide Stack

$804.96

View
Buy

Semaglutide

"OZEMPIC" PEPTIDE

From $95.00

View
Buy This product has multiple variants. The options may be chosen on the product page

Tirzepatide

"MOUNJARO" PEPTIDE

From $250.00

View
Buy This product has multiple variants. The options may be chosen on the product page